EDITOR
	Neil Love, MD Medical Oncologist Editor, Breast Cancer Update for Nurses Research To Practice Miami, Florida
FACULTY AFFILIATIONS
	Lee S Schwartzberg, MD Medical Director The West Clinic Clinical Professor of Medicine University of Tennessee School of Medicine Memphis, Tennessee		Rowan T Chlebowski, MD, PhD Professor of Medicine David Geffen School of Medicine at UCLA Chief, Division of Medical Oncology and Hematology Harbor-UCLA Medical Center Torrance, California
	Karen Dow Meneses, PhD, FAAN, RN Professor and Associate Dean for Research School of Nursing University of Alabama at Birmingham Birmingham, Alabama

CONTENT VALIDATION AND DISCLOSURES

Research To Practice is committed to providing its participants with high-quality, unbiased and state-of-the-art education. We assess potential conflicts of interest with faculty, planners and managers of CNE activities. Real or apparent conflicts of interest are identified and resolved by a peer review content validation process. The content of each activity is reviewed by both a member of the scientific staff and an external, independent reviewer for fair balance, scientific objectivity of studies referenced and patient care recommendations.

The scientific staff and consultants for Research To Practice are involved in the development and review of content for educational activities and report the following real or apparent conflicts of interest, either current or within the past 12 months, for themselves (or their spouses/partners) that have been resolved through a peer review process:

Lisa Aiello-Laws RN, MSN, APN,C, AOCNS, Richard Kaderman, PhD, Joanne Librie, RN, Neil Love, MD, Douglas Paley, Margaret Peng, Lilliam Sklaver Poltorack, PharmD, Erin Wall and Kathryn Ault Ziel, PhD — no real or apparent conflicts of interest to report; Aviva Asnis-Alibozek, PA-C, MPAS — salary: AstraZeneca Pharmaceuticals LP; shareholder of AstraZeneca Pharmaceuticals LP; Sally Bogert, RNC, WHCNP — shareholder of Amgen Inc and Genentech BioOncology; Anne O’Connor, RN, MSN, AOCN — shareholder of Abraxis BioScience. Research To Practice receives education grants from Abraxis BioScience, Amgen Inc, AstraZeneca Pharmaceuticals LP, Bayer Pharmaceuticals Corporation/Onyx Pharmaceuticals Inc, Biogen Idec, Genentech BioOncology/OSI Pharmaceuticals Inc, Genomic Health Inc, GPC Biotech, Roche Laboratories Inc and Sanofi-Aventis, who have no influence on the content development of our educational activities. In addition, the following faculty (and their spouses/partners) have reported real or apparent conflicts of interest that have been resolved through a peer review process:

Dr Schwartzberg — Speaker/Speakers Bureau: Amgen Inc, Genentech BioOncology, GlaxoSmithKline. Dr Meneses — Research Support: National Cancer Institute; Speaker/Speakers Bureau: Novartis Pharmaceuticals Corporation. Dr Chlebowski — Consultant: AstraZeneca Pharmaceuticals LP, Eli Lilly and Company, Novartis Pharmaceuticals Corporation, Organon, Sanofi-Aventis; Research Support: Eli Lilly and Company, Organon; Speaker/Speakers Bureau: AstraZeneca Pharmaceuticals LP, Genentech BioOncology, Novartis Pharmaceuticals Corporation.

---

This educational activity contains discussion of published and/or investigational uses of agents that are not indicated by the Food and Drug Administration. Research To Practice does not recommend the use of any agent outside of the labeled indications. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications and warnings. The opinions expressed are those of the presenters and are not to be construed as those of the publisher or grantors.

Table of Contents

Top of Page